Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for IRulya Therapeutics Inc. (IRLA : NSDQ)

• Company Description    IRulya Therapeutics Inc. transforming the lives of patients facing serious, underserved diseases by developing disease-modifying therapies to treat their conditions. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome post lung transplant and sarcoidosis associated pulmonary hypertension. IRulya Therapeutics Inc., formerly known as Quince Therapeutics Inc., is based in SAN FRANCISCO, Calif. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $34.68 Daily Weekly Monthly 20 Day Moving Average: 60,050 shares Shares Outstanding: 1.02 (millions) Market Capitalization: $35.27 (millions) Beta: 1.33 52 Week High: $909.98 52 Week Low: $15.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 15.02% 14.27% 12 Week 57.64% 48.67% Year To Date -94.82% -95.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 611 GATEWAY BOULEVARD SUITE 273 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 415-910-5717 fax: - cdavis@lifesciadvisors.com http://www.quincetx.com

• General Corporate Information    Officers Dirk Thye - Chief Executive Officer and Chief Medical Officer Brendan Hannah - Chief Operating Officer David A. Lamond - Director Christopher J. Senner - Director Una Ryan - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 22053A305 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 1.02 Most Recent Split Date: 6.00 (0.05:1) Beta: 1.33 Market Capitalization: $35.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.77 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-7.49 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 81.90% vs. Previous Quarter: -4.32% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - - 03/31/26 - - ROA 09/30/26 - - 06/30/26 - -133.84 03/31/26 - -67.99 Current Ratio 09/30/26 - - 06/30/26 - 14.52 03/31/26 - 2.92 Quick Ratio 09/30/26 - - 06/30/26 - 14.52 03/31/26 - 2.92 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - -34.73 03/31/26 - 19.23 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - - 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - - 03/31/26 - 0.00

Powered by Zacks Investment Research ©